Author:
Ragione F.,Faienza M. F.,Coppola B.,Mercurio C.,Pietra V.,Mastropietro S.,Borriello A.,Moretti A.,Giordani L.,Monno F.,Iolascon A.
Reference39 articles.
1. Cairns P, Mao L, Merlo Lee DJA, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund IE and Sidransky D (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415–417.
2. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 [MTS1] gene in pancreatic adenocarcinoma. Nat Genet 8: 27–32.
3. Chan FKM, Zhang J, Cheng L, Shapiro DN and Winoto A. (1995) Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol Cell Biol 15: 2682–2688.
4. Della Ragione F, Mercurio C and Iolascon A (1995) Cell cycle regulation and human leukemias: the role of p16INK4 gene inactivation in the development of human acute lymphoblastic leukemia. Haematologica 80: 562–573.
5. Desai D, Gu Y and Morgan DO (1992) Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell 3: 571–582.